We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Hits Hong Kong-Based Drugmaker Over cGMP Concerns Surrounding Procedures
FDA Hits Hong Kong-Based Drugmaker Over cGMP Concerns Surrounding Procedures
The FDA issued a warning letter Jan. 15 to a Hong Kong drugmaker for allegedly significant cGMP violations that led to adulterated products and data issues.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor